ProfileGDS5678 / 1424845_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 60% 59% 60% 59% 60% 59% 60% 59% 63% 60% 61% 64% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6325860
GSM967853U87-EV human glioblastoma xenograft - Control 23.5995460
GSM967854U87-EV human glioblastoma xenograft - Control 33.5504859
GSM967855U87-EV human glioblastoma xenograft - Control 43.5416660
GSM967856U87-EV human glioblastoma xenograft - Control 53.5227459
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.688760
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6222459
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5746760
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5426859
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7594463
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5940660
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5984761
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8447364
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7421763